Eisfeld Ann-Kathrin, Westerman Mark, Krahl Rainer, Leiblein Sabine, Liebert Uwe Gerd, Hehme Marianne, Teupser Daniel, Niederwieser Dietger, Al-Ali Haifa Kathrin
Department of Hematology/Oncology, University of Leipzig, Johannesallee 32a, 04103 Leipzig, Germany.
Adv Hematol. 2011;2011:491058. doi: 10.1155/2011/491058. Epub 2011 May 5.
Hepcidin is upregulated by inflammation and iron. Inherited (HFE genotype) and treatment-related factors (blood units (BU), Iron overload) affecting hepcidin (measured by C-ELISA) were studied in 42 consecutive patients with AML prior to and after allogeneic hematopoietic cell transplantation (HCT). Results. Elevated serum ferritin pre- and post-HCT was present in all patients. Median hepcidin pre- and post-HCT of 358 and 398 ng/mL, respectively, were elevated compared to controls (median 52 ng/mL) (P < .0001). Liver and renal function, prior chemotherapies, and conditioning had no impact on hepcidin. Despite higher total BU after HCT compared to pretransplantation (P < .0005), pre- and posttransplant ferritin and hepcidin were similar. BU influenced ferritin (P = .001) and hepcidin (P = .001). No correlation of pre- or posttransplant hepcidin with pretransplant ferritin was found. HFE genotype did not influence hepcidin. Conclusions. Hepcidin is elevated in AML patients pre- and post-HCT due to transfusional iron-loading suggesting that hepcidin synthesis remains intact despite chemotherapy and HCT.
铁调素受炎症和铁的上调作用影响。在42例接受异基因造血细胞移植（HCT）前后的急性髓系白血病（AML）患者中，研究了影响铁调素（通过C-ELISA检测）的遗传因素（HFE基因型）和治疗相关因素（输血单位（BU）、铁过载）。结果。所有患者在HCT前后血清铁蛋白均升高。与对照组（中位数52 ng/mL）相比，HCT前后铁调素的中位数分别为358和398 ng/mL，均升高（P <.0001）。肝功能、肾功能、既往化疗和预处理对铁调素无影响。尽管HCT后总的BU高于移植前（P <.0005），但移植前后的铁蛋白和铁调素相似。BU影响铁蛋白（P =.001）和铁调素（P =.001）。未发现移植前后铁调素与移植前铁蛋白之间存在相关性。HFE基因型不影响铁调素。结论。由于输血性铁负荷，AML患者在HCT前后铁调素升高，提示尽管经过化疗和HCT，铁调素的合成仍保持完整。
